Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin
NCT03699332Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of indium-111-DOTA-labetuzumab-IRDye800CW in peritoneal carcinomatosis (PC), sponsored by Radboud University Medical Center. Status: unknown.
02
Drugs
indium-111-DOTA-labetuzumab-IRDye800CW
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03699332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699332.